X

Conferences

In 2018, colorectal cancer (CRC) is estimated to affect 140,250 individuals in the United States and over one-half of these patients will develop liver metastases. Although surgical resection remains one of the major curative treatment options available to patients with colorectal liver metastases, it continues to be a controversial and evolving topic. As medical management and surgical techniques continue to advance in safety and efficacy, patients initially deemed unresectable can now be identified and have the potential to become resectable through preoperative treatment measures. In addition, given the extensive molecular and clinical heterogeneity of CRC, it is essential to individualize therapy on the basis of molecular profiling to avoid treatment-related toxicities without a recognized survival benefit.

Both primary liver cancer (HCC) and cholangiocarcinoma (CC) pose numerous clinical challenges. Over the last two years, the treatment landscape and biologic understanding of primary liver tumors has shifted dramatically with significant advancements in, loco-regional and systemic therapies rapidly being developed. Several large randomized phase III trials of novel treatments have resulted in new drug approvals and the increased knowledge of specific pathways implicated in tumor growth has shifted the focus of many clinical trials and treatments.

In light of these exciting new developments, this conference has been customized to provide the latest evidence based practice to health care professionals. Each session will address how expanding treatment choices and research studies will influence individual treatment plans and impact patient management in the future. Don’t miss out on this important and informative symposium.

DoubleTree by Hilton Hotel, Spokane City Center
322 North Spokane Falls Court
Spokane, WA




Upon completion of this activity, attendees should be able to:

  1. Define how to determine the initiation and sequence of therapies for patients with colorectal liver metastases
  2. Explain how the approach and timing of liver resection has changed the paradigm for surgical management of resectable synchronous colorectal liver metastases
  3. Summarize how molecular profiling can change diagnostic and treatment decisions
  4. Describe how location and lymph node involvement determines the type of surgical intervention for cholangiocarcinoma
  5. Assess the role and position of therapeutic options in determining proper treatment modalities for patients with cholangiocarcinoma
  6. Critique the clinical trial results and research data to determine the optimal timing and sequence of various treatment options for cholangiocarcinoma
  7. Review how molecular pathway alterations affect disease predisposition and etiology in cholangiocarcinoma
  8. Evaluate the risks and benefits of the novel techniques and therapeutic procedures that are impacting liver-directed therapies
  9. Discuss the significance of patient selection and the impact of tumor burden and location in determining which methodologies for liver tumors should be considered
  10. Incorporate the current advances in immunotherapies and combinatorial approaches for advanced HCC into a patient’s treatment plan
  11. Integrate optimal management strategies into a patient’s treatment plan by comparing and contrasting the most recent research and recognized guidelines
  12. Illustrate the value of creating a multidisciplinary team and communication system to improve quality of care and patient outcomes

FEES AND REGISTRATION

Physician$75.00
Other medical professional (RN/PA/LNP/RD)  $30.00
Fellow/Post Doc/Student$0.00

*Fellow/Post Doc/Student rate requires written confirmation of current status

The fee for this course includes catering, all instruction materials and transcript of AMA PRA Category 1 Credits™. Allow up to fifteen working days to receive your email confirmation of enrollment. If you have not received confirmation prior to your departure for the course, please contact the Continuing Medical Education office at 206.543.1050. Continuing Medical Education will not be responsible for expenses incurred by an individual who is not confirmed and for whom space is not available at the course.

IMPORTANT PAYMENT INFORMATION
Per UWCME policy, you are not considered to be registered for the course until full payment has been received. Unpaid orders do not "reserve" spots for conferences or workshops.

CANCELLATION POLICY
The Office of Continuing Medical Education must receive written notification of your cancellation by September 14, 2018. No refunds will be issued. The Office of Continuing Medical Education reserves the right to cancel this course twenty (20) days prior to the course date when a minimum enrollment is not met or for other reasons that prevent the University from holding the course. Each registrant will be notified by telephone followed by written notification and a full refund. The University of Washington is not responsible for any other costs incurred such as non-refundable airline tickets or hotel penalties. Contact CME with questions - call 206.543.1050, fax 206.221.4525 or email cme@uw.edu.

Smith Apisarnthanarax, MD
Associate Professor of Medicine, Department of Radiation Oncology
University of Washington
Seattle, WA
Greta Bernier, MD
Assistant Professor, Department of Surgery
University of Washington
Seattle, WA
Michael Brophy, MD
Gastroenterologist
MultiCare Health System
Spokane, WA
Arvind Chaudhry, MD, PhD
Medical Oncologist
Summit Cancer Centers
Spokane, WA
Stacey Cohen, MD
Assistant Professor of Medicine, Division of Medical Oncology
University of Washington
Seattle, WA
Mitchell Garrison, MD
Medical Oncologist
Confluence Health
Wenatchee, WA
William P Harris, MD
Associate Professor, Department of Medicine, Division of Oncology
University of Washington
Seattle, WA
Guy Johnson, MD, PharmD
Assistant Professor, Department of Radiology, Division of Interventional Radiology
University of Washington
Seattle, WA
Karie-Lynn Kelly, MD
Radiation Oncologist
Summit Cancer Centers
Spokane Valley, WA
Amer Khouri, MD
Medical Oncologist
Trios Health
Kennewick, WA
James O Park, MD
Associate Professor, Department of Surgery
University of Washington
Seattle, WA
Aaron Saunders, MD
Surgical Oncologist
Summit Cancer Centers
Spokane, WA
Kit Wong, MD
Assistant Professor of Medicine, Division of Medical Oncology
University of Washington
Seattle, WA
Raymond Yeung, MD
Professor of Medicine, Department of Surgery
University of Washington
Seattle, WA
Title Time Faculty Room
Registration and Continental Breakfast 7:30AM - 8:00AM  
Welcome 8:00AM - 8:05AM William P Harris, MD
Raymond Yeung, MD
 
Perioperative Chemotherapy for Curative Intent 8:05AM - 8:25AM Stacey Cohen, MD
 
Session 1: Colorectal Liver Metastases: Multimodality Sequencing 8:05AM - 10:00AM  
Redefining Resectability 8:25AM - 8:45AM James O Park, MD
 
Combined Hepatectomy with Colorectal Resection 8:45AM - 9:05AM Greta Bernier, MD
 
Case Presentations with Tumor Board 9:05AM - 9:45AM Arvind Chaudhry, MD, PhD
Aaron Saunders, MD
 
Q & A 9:45AM - 10:00AM  
Break 10:00AM - 10:15AM  
Session 2: Colorectal Liver Metastases: Molecular Profiling 10:15AM - 10:40AM  
Updates and Clinical Applications of Molecular Profiling 10:15AM - 10:35AM Stacey Cohen, MD
 
Q & A 10:35AM - 10:40AM  
Session 3: Cholangiocarcinoma: A Multidisciplinary Approach 10:40AM - 12:30PM  
Surgical Management 10:40AM - 11:00AM James O Park, MD
 
Systemic Therapy for Resectable and Unresectable Disease 11:00AM - 11:20AM Kit Wong, MD
 
Emerging Targeted Therapies and Molecular Subtypes 11:20AM - 11:40AM William P Harris, MD
 
Case Presentations with Tumor Board 11:40AM - 12:20PM Mitchell Garrison, MD
Amer Khouri, MD
 
Q & A 12:20PM - 12:30PM  
Lunch (provided) 12:30PM - 1:15PM  
Radioembolization 1:15PM - 1:35PM Guy Johnson, MD, PharmD
 
Session 4: Hepatocellular Carcinoma (HCC): Liver-Directed Therapies 1:15PM - 2:45PM  
External Beam Radiotherapies 1:35PM - 1:55PM Smith Apisarnthanarax, MD
 
Choosing A Locoregional Modality 1:55PM - 2:15PM Raymond Yeung, MD
 
Case Presentation with Tumor Board 2:15PM - 2:35PM Karie-Lynn Kelly, MD
 
Q & A 2:35PM - 2:45PM  
Break 2:45PM - 3:00PM  
Novel Systemic Therapy Approaches for HCC 3:00PM - 3:20PM William P Harris, MD
 
Session 5: Hepatocellular Carcinoma (HCC): Future Directions in Medical Management 3:00PM - 3:55PM  
Case Presentation with Tumor Board 3:20PM - 3:40PM Michael Brophy, MD
 
Q & A 3:40PM - 3:55PM  
Closing Remarks 3:55PM - 4:00PM James O Park, MD
Kit Wong, MD
 
Adjourn 4:00PM - 4:05PM  
Accreditation with Commendation: The University of Washington School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation: The University of Washington School of Medicine designates this live activity for a maximum of 6.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOTEL ACCOMMODATIONS

To make reservations, please call the hotel directly or use the reservation link below.

DoubleTree by Hilton Spokane City Center
322 North Spokane Falls Court
Spokane, WA 99201
Reservations 1-800-757-6131, ask for the Liver Cancer Symposium group rate

TARGET AUDIENCE
Physicians, clinical researchers, nurse practitioners, nurses, physician assistants, fellows/residents, in the specialties of oncology, surgery, gastroenterology, interventional radiology, internal medicine, and primary care.

ONLINE CONFERENCE MATERIALS
Instruction materials will be available for download at uwcme.org (for conference registrants only). Materials will be available starting on September 24, 2018, for registrants to print and/or download. A booklet with the conference agenda and pages for note-taking will be provided at the conference. No printed materials will be available.

ATTENDANCE POLICY
Course activities are exclusively reserved for course attendees. Badges provided at registration are required for entrance into all functions and will be strictly enforced.

DIETARY REQUESTS
UW CME takes into consideration diverse nutritional preferences and restrictions when planning our complimentary menu. However, those individuals who might find that our menu is not completely aligned to their specific nutritional needs are welcome to bring their own food items.

If you have dietary restrictions (e.g., vegan, gluten-free, etc.), please notify us by sending an email to cme@uw.edu by September 14, 2018. 

SPECIAL SERVICES
Please inform the CME Office ten days in advance of the conference start date if you will need to utilize lactation services.

Continuing Medical Education at the University of Washington is a self-sustaining unit and does not depend on or receive public monies in support of its educational efforts. Fees for this course are estimated to cover the costs of conducting this course. These costs include salaries, registration, course credit, handouts, record keeping, faculty planning and evaluation and may include food, beverages, taxes and gratuities to vendors. The University of Washington reaffirms its policy of equal opportunity regardless of race, color, creed, religion, national origin, sex, sexual orientation, age, marital status, disability or status as a disabled veteran or Vietnam era veteran in accordance with University policy and applicable federal and state statutes and regulations. The University of Washington is committed to providing access and reasonable accommodation in its services, programs, activities, education and employment for individuals with disabilities. To request disability accommodation, please contact the Disability Services Office at least ten days in advance.

Disability Services Office
206.543.6450/Voice • 206.543.6452/TTY • 206.685.7264/Fax • e-mail: dso@uw.edu



Follow UW CME on Facebook and Twitter.

Would you like to support UW CME? Click here to donate now.


Privacy | Contact Us | Terms | UW Medicine